secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2023-10-12T23:59:59+00:00
Accession:  0001193125-23-254659
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio starts Phase 2 GBM trial (INB-400) and completes Phase 1 dose escalation (INB-100)
--------------------------------------------------------------------------------

- Enrollment open for Phase 2 trial of INB-400 in newly diagnosed GBM; plans ~40 patients in Arm A; primary endpoint 12-month OS.
- Dose escalation phase of Phase 1 INB-100 trial in leukemia closed; clinical update expected at ASH Dec 9-12, 2023.
- As of April 2023, 100% of evaluable patients (n=7) on INB-100 in durable complete remission; one patient progression-free >3 years.
- First activated sites for INB-400: University of Louisville and Cleveland Clinic; INB-400 received FDA Orphan Drug Designation April 2023.
- R&D Day held October 12, 2023; webcast available.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000119312523254659/0001193125-23-254659-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000119312523254659/d535806d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-254659

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer